Compare GameStop Corp. (GME) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs ResMed Inc. — how do they compare? GameStop Corp. trades at $22.06 (market cap $9.99B), while ResMed Inc. trades at $202.06 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 2.9× GameStop Corp.'s market cap, and ResMed Inc. pays a 1.21% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GME | RMD | |
|---|---|---|
Market Cap | $9.99B | $28.80B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $293.73 |
52-Week Low | $19.94 | $182.82 |
Enterprise Value | $5.96B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $22.36, down 0.31% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue declined to $3.82 billion in 2025, but net income improved to $131.3 million, reflecting a profit margin of 3.43%. Recent developments include a partnership with Uber Eats and ongoing efforts to acquire eBay, as announced in Business Wire on June 26, 2026.
The outlook is mixed, with positive EBITDA guidance above $600 million for fiscal 2026 offering upside potential, but risks include revenue declines and dependence on physical media amid Sony's shift away from discs. Analyst sentiment is cautious, with only 16.67% buy ratings, suggesting limited near-term conviction despite operational improvements.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
